Literature DB >> 17453448

Therapeutic outcomes of laryngeal cancer at Kyoto University Hospital for 10 years.

Yoshihiro Tamura1, Shinzo Tanaka, Ryo Asato, Shigeru Hirano, Masaru Yamashita, Hisanobu Tamaki, Juichi Ito.   

Abstract

CONCLUSION: It is important to prevent regional lymph node recurrence and distant metastasis to achieve better survival of laryngeal cancer.
OBJECTIVE: Therapeutic outcomes of 130 cases with laryngeal cancer treated at Kyoto University Hospital between 1995 and 2004 were reviewed. PATIENTS AND METHODS: In all, 121 males and 9 females were involved. Their ages ranged from 40 years to 92 years (average 66 years). All tumors were squamous cell carcinoma - arising at the glottis in 111 cases, the supraglottis in 18, and the subglottis in 1 case. Most glottic cancers (77.5%) were classified as stage I or II, while most supraglottic cancers (77.8%) were at stage III or IV. Stage I/II cancers were basically treated by conventional radiotherapy (60-66 Gy) and twice-daily hyperfractionated radiotherapy (70-74 Gy), respectively, attempting to preserve the larynx. Total laryngectomy with neck dissection was performed in the treatment of stage III/IV cases.
RESULTS: Five-year disease-specific survival rates were 100%, 96%, 100%, and 68% for stage I, II, III, and IV, respectively. Five-year laryngeal preservation rates were 98%, 100%, 86%, 0%, and 0% for T1a, T1b, T2, T3, and T4 of glottic cancer, respectively. Local recurrence occurred in five cases of stage I/II glottic cancer, which was successfully salvaged. Regional lymph node recurrence occurred in five cases including four patients with glottic cancer and one with supraglottic cancer. Two of them died of disease despite undergoing salvage therapy. Distant metastasis occurred in the lung in four cases including one glottic and three supraglottic cancer patients after initial treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17453448     DOI: 10.1080/00016480601067990

Source DB:  PubMed          Journal:  Acta Otolaryngol Suppl        ISSN: 0365-5237


  7 in total

Review 1.  Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis.

Authors:  Elisabeth Rudolph; Gerhard Dyckhoff; Heiko Becher; Andreas Dietz; Heribert Ramroth
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-10-19       Impact factor: 2.503

Review 2.  Current trends in initial management of laryngeal cancer: the declining use of open surgery.

Authors:  Carl E Silver; Jonathan J Beitler; Ashok R Shaha; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-07-14       Impact factor: 2.503

3.  shRNA-targeted cyclooxygenase (COX)-2 inhibits proliferation, reduces invasion and enhances chemosensitivity in laryngeal carcinoma cells.

Authors:  Rui Wang; Xi Wang; Fang Lin; Ping Gao; Ke Dong; Hui-Zhong Zhang
Journal:  Mol Cell Biochem       Date:  2008-07-01       Impact factor: 3.396

4.  Functional organ preservation in laryngeal and hypopharyngeal cancer.

Authors:  Petra Ambrosch; Asita Fazel
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-04-26

5.  SPINK5 is a Prognostic Biomarker Associated With the Progression and Prognosis of Laryngeal Squamous Cell Carcinoma Identified by Weighted Gene Co-Expression Network Analysis.

Authors:  Jian Liu; Jing Zhao; Jiaran Xu; Qing Sun; Xuemei Qin; Guohui Chen; Tianle Gao; Guangping Bai; Zhiqiang Guo
Journal:  Evol Bioinform Online       Date:  2022-02-04       Impact factor: 1.625

6.  Transoral laser surgery for recurrent glottic cancer after radiotherapy: oncologic and functional outcomes.

Authors:  F Del Bon; C Piazza; S Mangili; L O Redaelli De Zinis; P Nicolai; G Peretti
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-08       Impact factor: 2.124

7.  Overexpression of Beclin1 inhibits proliferation and promotes apoptosis of human laryngeal squamous carcinoma cell Hep-2.

Authors:  Baoluo Wan; Yanzi Zang; Lin Wang
Journal:  Onco Targets Ther       Date:  2018-07-04       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.